China SXT Pharmaceuticals (NASDAQ:SXTC) Stock Price Down 0.4% – Should You Sell?

Posted by Francis Steltz on Jul 17th, 2026

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report)’s stock price dropped 0.4% during trading on Thursday . The company traded as low as $2.38 and last traded at $2.57. 9,698 shares were traded during mid-day trading, a decline of 75% from the average session volume of 38,406 shares. The stock had previously closed at $2.58.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, July 10th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Read Our Latest Report on SXTC

China SXT Pharmaceuticals Stock Performance

The stock’s fifty day simple moving average is $2.02 and its two-hundred day simple moving average is $18.65. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02.

China SXT Pharmaceuticals (NASDAQ:SXTC – Get Free Report) last posted its quarterly earnings results on Wednesday, July 1st. The company reported ($0.07) earnings per share (EPS) for the quarter. The firm had revenue of $0.26 million for the quarter.

Hedge Funds Weigh In On China SXT Pharmaceuticals

A number of large investors have recently bought and sold shares of SXTC. Citadel Advisors LLC acquired a new position in China SXT Pharmaceuticals in the third quarter valued at approximately $78,000. XTX Topco Ltd acquired a new stake in shares of China SXT Pharmaceuticals during the 4th quarter worth approximately $36,000. Finally, Virtu Financial LLC lifted its holdings in shares of China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock worth $46,000 after purchasing an additional 15,013 shares during the last quarter. Institutional investors own 5.02% of the company’s stock.

About China SXT Pharmaceuticals

(Get Free Report)

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.